GlassScriptPhysician profile
Abdul Baset Khan
NPI 1033286166
$1,324.70
in general payments reported to CMS, 2019-2025
21 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $31.31 · 2021: $51.43 · 2022: $347 · 2023: $157 · 2024: $230 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.66 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $217.53 | 2022-2023 | Rayaldee |
| Abbvie INC. | $172.77 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $126.73 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $124.93 | 2025 | Fanapt |
| Abbott Laboratories | $114.98 | 2022 | |
| Novo Nordisk INC | $96.87 | 2024-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.92 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $62.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $61.68 | 2019-2025 | Strensiq |
| Amgen INC. | $59.04 | 2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $26.11 | 2025 | Wainua |
| Biogen, INC. | $24.87 | 2024 | Spinraza |
| Indivior INC. | $24.44 | 2024 | Sublocade |
| Bausch Health US, LLC | $22.89 | 2024 | Aplenzin, Wellbutrin |
| Eisai INC. | $22.37 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.08 | 2025 | Voquezna |
| Alkermes, INC. | $14.85 | 2023 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $14.66 | 2019 | |
| Neuronetics, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.